RHCE genotype and production of anti-C, -e, or -E: clinical significance, donor exposures, and antibody duration
| Antibody specificity . | Concurrent Antibodies . | ID . | RH genotype . | DTR . | RBC exposures . | Antibody demon-stration (months) . | |||
|---|---|---|---|---|---|---|---|---|---|
| RHCE . | RHD . | ||||||||
| C+ patients lacking conventional RHCE*Ce | |||||||||
| C (n = 5) | 100 | ceS | ce(733G) | DIIIa-CE(4-7)-D | RHD | No | 52 | 39 | |
| 94 | ceS | ce | DIIIa-CE(4-7)-D | RHD | No | 115 | 4 | ||
| 105* | ceS | cE | DIIIa-CE(4-7)-D | RHD | No | 12 | — | ||
| 85 | ceS | ceTI | DIIIa-CE(4-7)-D | DIVa-2 | Yes | 65 | 13 | ||
| 118 | ceS | ceTI | DIIIa-CE(4-7)-D | DIVa-3 | — | — | — | ||
| C+ patients with one conventional RHCE*Ce | |||||||||
| C (n = 4) | D | 138 | Ce | ceS | RHD | DIIIa-CE(4-7)-D | Yes | 103 | 1 |
| 95 | Ce | ceTI | RHD | Deleted D | Yes | 365 | 2 | ||
| 96 | Ce | ce(733G) | RHD | Deleted D | No | 82 | 32 | ||
| 21 | Ce | ce(733G) | RHD | Deleted D | — | — | — | ||
| e+ patients lacking conventional RHCE*ce | |||||||||
| e (n = 14) | C | 97* | ce(48C) | ce(48C) | RHD | RHD | Yes | 1 | — |
| 75 | ce(48C) | ce(48C) | DAU0 | DAU5 | No | 91 | 1 | ||
| 108 | ce(48C) | ce(733G) | DAU0 | Inactive RHD ψ | Yes | 107 | 1 | ||
| 102 | ce(48C) | ce(733G) | DAU0 | RHD | No | 295 | 24 | ||
| 148 | ce(48C) | ce(733G) | Weak partial 4.0 | Weak partial 4.0 | No | 6 | 4 | ||
| 65 | ce(48C) | ceS | DAU3 | DIIIa | Yes | 174 | 19 | ||
| 63 | ce(48C) | ceS | DAU0 | DIIIa-CE(4-7)-D | No | 195 | 1 | ||
| 100 | ce(733G) | ceS | RHD | DIIIa-CE(4-7)-D | Yes | 62 | 36 | ||
| 96 | ce(733G) | Ce | Deleted D | RHD | No | 64 | 10 | ||
| 93 | ce(733G) | Ce | RHD | RHD | No | 24 | 1 | ||
| 45 | ce(733G) | cE | RHD | RHD | — | — | — | ||
| 86 | ce(48C,733G) | cE | Weak partial 4.0 | RHD | Yes | 8 | 1 | ||
| C | 98 | ce(254G) | cE | RHD | Deleted D | No | 92 | 11 | |
| C | 60 | ce(254G) | cE | DAU0 | RHD | No | 40 | 22 | |
| e+ patients with one conventional RHCE*ce | |||||||||
| e (n = 2) | 27 | ce | ce(48C) | RHD | DAU0 | No | 396 | 49 | |
| 94 | ce | ceS | RHD | DIIIa-CE(4-7)-D | No | 281 | 2 | ||
| E+ patients with one conventional RHCE*cE | |||||||||
| E (n = 2) | 17 | cE | ce | RHD | Deleted D | — | 279 | 1 | |
| D | 104 | cE | ce(48C) | DAU3 | DAU5 | No | 39 | 19 | |
| Antibody specificity . | Concurrent Antibodies . | ID . | RH genotype . | DTR . | RBC exposures . | Antibody demon-stration (months) . | |||
|---|---|---|---|---|---|---|---|---|---|
| RHCE . | RHD . | ||||||||
| C+ patients lacking conventional RHCE*Ce | |||||||||
| C (n = 5) | 100 | ceS | ce(733G) | DIIIa-CE(4-7)-D | RHD | No | 52 | 39 | |
| 94 | ceS | ce | DIIIa-CE(4-7)-D | RHD | No | 115 | 4 | ||
| 105* | ceS | cE | DIIIa-CE(4-7)-D | RHD | No | 12 | — | ||
| 85 | ceS | ceTI | DIIIa-CE(4-7)-D | DIVa-2 | Yes | 65 | 13 | ||
| 118 | ceS | ceTI | DIIIa-CE(4-7)-D | DIVa-3 | — | — | — | ||
| C+ patients with one conventional RHCE*Ce | |||||||||
| C (n = 4) | D | 138 | Ce | ceS | RHD | DIIIa-CE(4-7)-D | Yes | 103 | 1 |
| 95 | Ce | ceTI | RHD | Deleted D | Yes | 365 | 2 | ||
| 96 | Ce | ce(733G) | RHD | Deleted D | No | 82 | 32 | ||
| 21 | Ce | ce(733G) | RHD | Deleted D | — | — | — | ||
| e+ patients lacking conventional RHCE*ce | |||||||||
| e (n = 14) | C | 97* | ce(48C) | ce(48C) | RHD | RHD | Yes | 1 | — |
| 75 | ce(48C) | ce(48C) | DAU0 | DAU5 | No | 91 | 1 | ||
| 108 | ce(48C) | ce(733G) | DAU0 | Inactive RHD ψ | Yes | 107 | 1 | ||
| 102 | ce(48C) | ce(733G) | DAU0 | RHD | No | 295 | 24 | ||
| 148 | ce(48C) | ce(733G) | Weak partial 4.0 | Weak partial 4.0 | No | 6 | 4 | ||
| 65 | ce(48C) | ceS | DAU3 | DIIIa | Yes | 174 | 19 | ||
| 63 | ce(48C) | ceS | DAU0 | DIIIa-CE(4-7)-D | No | 195 | 1 | ||
| 100 | ce(733G) | ceS | RHD | DIIIa-CE(4-7)-D | Yes | 62 | 36 | ||
| 96 | ce(733G) | Ce | Deleted D | RHD | No | 64 | 10 | ||
| 93 | ce(733G) | Ce | RHD | RHD | No | 24 | 1 | ||
| 45 | ce(733G) | cE | RHD | RHD | — | — | — | ||
| 86 | ce(48C,733G) | cE | Weak partial 4.0 | RHD | Yes | 8 | 1 | ||
| C | 98 | ce(254G) | cE | RHD | Deleted D | No | 92 | 11 | |
| C | 60 | ce(254G) | cE | DAU0 | RHD | No | 40 | 22 | |
| e+ patients with one conventional RHCE*ce | |||||||||
| e (n = 2) | 27 | ce | ce(48C) | RHD | DAU0 | No | 396 | 49 | |
| 94 | ce | ceS | RHD | DIIIa-CE(4-7)-D | No | 281 | 2 | ||
| E+ patients with one conventional RHCE*cE | |||||||||
| E (n = 2) | 17 | cE | ce | RHD | Deleted D | — | 279 | 1 | |
| D | 104 | cE | ce(48C) | DAU3 | DAU5 | No | 39 | 19 | |
DTR, DTR from Table 2; RBC exposures, cumulative number of units transfused prior to antibody detection; antibody demonstration, the number of months antibody was detected. Additional antibody detected concurrently is indicated in the second column. —, data not available.
Episodically transfused patient.